Coherus Oncology

Coherus Oncology

CHRS· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +2.9% in FY2025

Dennis M. Lanfear is the CEO of Coherus Oncology and was paid $2.7M in FY2025 (Dec), down 43%.

Pay$100 in the stock at the end of FY20 → $8
CEO pay is from each Coherus Oncology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Dennis M. LanfearFY2025
  2. 2Paul ReiderFY2025
  3. 3Bryan McMichaelFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Coherus Oncology paid its 3 named executives $5.1M in total in FY2025 (Dec). CEO Dennis M. Lanfear was paid $2.7M of that.

Name
Dennis M. LanfearPresident, Chief Executive Officer and Chairman of the Board of Directors
Paul ReiderFormer Chief Commercial Officer
Bryan McMichaelChief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers21

See all

The FY2023 (Dec) proxy of Coherus Oncology names 21 peer companies for pay. Among Coherus Oncology and these peers, CEO pay was 5th highest of 8 and total shareholder return was the lowest of 8.

5th highest of 8in Coherus Oncology and its pay peers, FY2023 (Dec) by CEO pay:

$3.1M$8.9M

8th highest of 8in Coherus Oncology and its pay peers, FY2023 (Dec) by total shareholder return:

-$82$185

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board5

See all
  • Mats L. WahlströmLead independent director · 13 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
  • Ali J. SatvatDirector · 11 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
  • Jill O’Donnell-TormeyDirector · 3 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Michael RyanDirector · 2 yr on the boardIndependentCompensation—Paid as an executive
  • Georgia ErbezDirector · 1 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Coherus Oncology Former Chief Commercial Officer pay fell 26% to $1.2M. The stock rose 3% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Coherus Oncology CEO pay fell 43% to $2.7M. The stock rose 3% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Coherus Oncology Former Chief Commercial Officer pay fell 14% to $1.7M. The stock fell 59% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Coherus Oncology CEO pay fell 19% to $4.8M. The stock fell 59% in FY2024 (Dec).
    DEF 14A
  5. Board
    Georgia Erbez joined the board of Coherus Oncology. Georgia Erbez sits on no other public board.
    3
  6. Pay
    Coherus Oncology former Chief Scientific Officer pay fell 23% to $2.2M. The stock fell 50% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Coherus Oncology Former CFO pay rose 10% to $2.3M. The stock fell 58% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Coherus Oncology Former CFO pay rose 41% to $2.1M. The stock fell 50% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Coherus Oncology CEO pay fell 14% to $5.9M. The stock fell 58% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Coherus Oncology CEO pay fell 20% to $6.9M. The stock fell 50% in FY2022 (Dec).
    DEF 14A
  11. Board
    Michael Ryan joined the board of Coherus Oncology. Michael Ryan sits on no other public board.
    3
  12. Board
    Georgia Erbez joined the board of Coherus Oncology. Georgia Erbez sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 20, 2026FY2025
Annual report10-KMar 9, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 17, 2025FY2024
Proxy statementDEF 14AApr 15, 2024FY2023
Annual report10-KMar 15, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data